Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127


A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.

Macdougall IC, Strauss WE, McLaughlin J, Li Z, Dellanna F, Hertel J.

Clin J Am Soc Nephrol. 2014 Apr;9(4):705-12. doi: 10.2215/CJN.05320513. Epub 2014 Jan 23.


Ferumoxytol: an intravenous iron, riskier than iron sucrose.

[No authors listed]

Prescrire Int. 2013 Sep;22(141):206. No abstract available.


Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron.

Vadhan-Raj S, Strauss W, Ford D, Bernard K, Boccia R, Li J, Allen LF.

Am J Hematol. 2014 Jan;89(1):7-12. doi: 10.1002/ajh.23582. Epub 2013 Sep 30.


Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease.

Kowalczyk M, Banach M, Rysz J.

J Nephrol. 2011 Nov-Dec;24(6):717-22. doi: 10.5301/jn.5000025. Review.


Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.

Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ.

Clin J Am Soc Nephrol. 2009 Feb;4(2):386-93. doi: 10.2215/CJN.02840608. Epub 2009 Jan 28.


A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia.

Derman R, Roman E, Modiano MR, Achebe MM, Thomsen LL, Auerbach M.

Am J Hematol. 2017 Mar;92(3):286-291. doi: 10.1002/ajh.24633. Epub 2017 Feb 1.


Ferumoxytol for treating iron deficiency anemia in CKD.

Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, Brenner L, Pereira BJ.

J Am Soc Nephrol. 2008 Aug;19(8):1599-605. doi: 10.1681/ASN.2007101156. Epub 2008 Jun 4.


A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.

BirgegÄrd G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M.

Pharmacotherapy. 2016 Apr;36(4):402-14. doi: 10.1002/phar.1729. Epub 2016 Apr 1.


A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).

Reinisch W, Staun M, Tandon RK, Altorjay I, Thillainayagam AV, Gratzer C, Nijhawan S, Thomsen LL.

Am J Gastroenterol. 2013 Dec;108(12):1877-88. doi: 10.1038/ajg.2013.335. Epub 2013 Oct 22.


Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min.

Auerbach M, Strauss W, Auerbach S, Rineer S, Bahrain H.

Am J Hematol. 2013 Nov;88(11):944-7. doi: 10.1002/ajh.23534. Epub 2013 Sep 9.


Intravenous iron sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy: a randomized clinical trial.

Kochhar PK, Kaundal A, Ghosh P.

J Obstet Gynaecol Res. 2013 Feb;39(2):504-10. doi: 10.1111/j.1447-0756.2012.01982.x. Epub 2012 Aug 26.


A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.

Coppol E, Shelly J, Cheng S, Kaakeh Y, Shepler B.

Ann Pharmacother. 2011 Feb;45(2):241-7. doi: 10.1345/aph.1P466. Review.


Ferumoxytol versus iron sucrose treatment: a post-hoc analysis of randomized controlled trials in patients with varying renal function and iron deficiency anemia.

Strauss WE, Dahl NV, Li Z, Lau G, Allen LF.

BMC Hematol. 2016 Jul 26;16:20. doi: 10.1186/s12878-016-0060-x. eCollection 2016.


Safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy: Results of a phase III, open-label, 6-month extension study.

Vadhan-Raj S, Ford DC, Dahl NV, Bernard K, Li Z, Allen LF, Strauss WE.

Am J Hematol. 2016 Feb;91(2):E3-5. doi: 10.1002/ajh.24240. No abstract available.


Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease.

Schwenk MH.

Pharmacotherapy. 2010 Jan;30(1):70-9. doi: 10.1592/phco.30.1.70. Review.


Intravenous iron sucrose for children with iron deficiency anemia: a single institution study.

Mantadakis E, Tsouvala E, Xanthopoulou V, Chatzimichael A.

World J Pediatr. 2016 Feb;12(1):109-13. doi: 10.1007/s12519-015-0010-x. Epub 2015 Mar 9.


The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.

Macdougall IC, Dahl NV, Bernard K, Li Z, Batyky A, Strauss WE.

BMC Nephrol. 2017 Apr 3;18(1):117. doi: 10.1186/s12882-017-0523-8.


Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding.

Mahey R, Kriplani A, Mogili KD, Bhatla N, Kachhawa G, Saxena R.

Int J Gynaecol Obstet. 2016 Apr;133(1):43-8. doi: 10.1016/j.ijgo.2015.09.007. Epub 2015 Dec 23.


Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period.

Schiller B, Bhat P, Sharma A.

Clin Ther. 2014 Jan 1;36(1):70-83. doi: 10.1016/j.clinthera.2013.09.028. Epub 2013 Dec 7.


Supplemental Content

Support Center